The involvement of reactive oxygen species (ROS) in morphine-induced analgesia and tolerance has been suggested, yet how and where ROS take part in these processes remains largely unknown. Here, we report a novel role for the superoxide-generating enzyme NOX1/ NADPH oxidase in the regulation of analgesia and acute analgesic tolerance. In mice lacking Nox1 (Nox1 
Introduction
Opioids are among the most effective analgesics currently in use. However, the efficacy of morphine is limited by the rapid development of tolerance. Up to the present, roles of reactive oxygen and nitrogen species in the development of morphine antinociceptive tolerance have been documented (Rokyta et al., 2003; Muscoli et al., 2007; Doyle et al., 2009) . Of particular interest is the fact that morphine-induced tolerance was associated with activation of spinal NADPH oxidase (Doyle et al., 2010) . This finding introduced the possibility that the enzyme may be a critical source of reactive oxygen species mediating nociceptive signaling. NADPH oxidase is a superoxide-generating flavoenzyme comprising a membrane-bound catalytic subunit NOX and several cytosolic regulatory subunits. NOX has several homologs, including NOX2 implicated in neurodegenerative and psychiatric disorders (Sorce and Krause, 2009 ). NOX2 was also reported to take part in the development of neuropathic pain induced by nerve injury (Kim et al., 2010) . NOX1 is not well understood, and although its role in some organs is being elucidated (Matsuno et al., 2005 , Cui et al., 2011 , its function in the nervous system is still unclear. Previously, we demonstrated the involvement of NOX1 in hyperalgesia using mice lacking the Nox1 gene (Nox1 Ϫ/Y ) (Ibi et al., 2008) . While the molecular mechanisms underlying the development of opioid-induced tolerance have not been fully clarified, desensitization appears to contribute to tolerance. Morphine desensitizes the receptor via a protein kinase C (PKC)-dependent pathway (Johnson et al., 2006) , while a synthetic opioid agonist desensitizes MOR -opioid receptor by G-protein-coupled receptor kinase (GRK) dependent internalization and the resultant downregulation of MOR expression (Zhang et al., 1998) . Regulator of G-protein signaling (RGS) proteins were identified as taking part in the receptor's desensitization independent of its internalization and downregulation (Garzó n et al., 2001) . In fact, a study in primary cultured neurons showed that desensitization occurs independent of internalization (Arttamangkul et al., 2006) . RGS proteins share a conserved domain with GTPaseactivating protein (GAP) activity, and accelerate the hydrolysis of guanosine triphosphate (GTP) by G␣, thus limiting the duration of G-protein coupled receptor (GPCR) signaling. RGS9-2 is a splice variant of the rgs9 gene with a unique pattern of localization in regions mediating responses to opiates (Gold et al., 1997; Rahman et al., 1999) . Acute morphine administration increased expression of RGS9-2 in the nervous system, and mice lacking RGS9 show increased morphine analgesia with delayed tolerance (Zachariou et al., 2003) . Intriguingly, phosphorylation of the RGS protein by various kinases including PKC has been documented to regulate GAP activity (Willars, 2006) . In preceding communication, we reported that activation of PKC by ROS derived from NOX1 was the key mechanism underlying the development of hyperalgesia (Ibi et al., 2008) . As a logical extension of these findings, a possible correlation may exist between NOX1/NADPH oxidase and desensitization of MOR.
This led us to undertake the investigation of whether NOX1/NADPH oxidase is the source of ROS-mediating opiate responses. We report here a novel role for NOX1/NADPH oxidase in morphineinduced analgesia and acute analgesic tolerance by regulating GTPase activity and phosphorylation of RGS9-2 by PKC.
Materials and Methods
Reagents. Morphine-HCl was obtained from Takeda Pharmaceutical Company. The antibodies against RGS9, 14-3-3, G␣i2, PKC␦, PKC, and PKC␥ were purchased from Santa Cruz Biotechnology. The anti-PKC␣ antibody was obtained from BD Biosciences. The phospho-(Ser) PKC substrate antibody was obtained from CST. EZ-Link-sulfo-NHS-LC-Biotin, NeutrAvidinagarose was obtained from Pierce. Hydroethidine was from Invitrogen and L012 from Wako Pure Chemicals Industries. The PrimeScript RT reagent Kit and SYBR Premix EX Taq II were purchased from Takara. The RNeasy Micro Kit was obtained from Qiagen. The protease inhibitor cocktail, phosphatase inhibitor cocktail, and CanGet Signal were obtained from Nacalai Tesque.
Animals. Male mice deficient in Nox1 (Nox1 Ϫ/Y ) and control littermates (Nox1 ϩ/Y ) were housed in a temperature-controlled room (21-23°C) with a 12 h light/dark cycle. For the present experiments, 11-12-week-old mice were used. All procedures were done in accordance with the policies and recommendations of the International Association for the Study of Pain and were approved by the Committee for Animal Research at Kyoto Prefectural University of Medicine.
Assessment of nociception. Mechanical nociception and thermal nociception were evaluated as described previously (Ibi et al., 2008) . In brief, thermal nociception was determined as the latency to paw licking and tapping in the hot plate test (54°C). The cutoff time was 30 s. Pressure (20 g/s) was gradually applied to the tail of mice and nociceptive thresholds were determined as the pressure (g) required to elicit tail withdrawal. The cutoff weight was 500 g. The morphine-induced analgesia was evaluated as the latency to mechanical and thermal nociceptive stimuli. The test was performed 30 -90 min after the morphine administration. To investigate the development of tolerance following the repeated administration of morphine, mice were given morphine (10 mg/kg, i.p.) once a day for 7 consecutive days. Antinociception was calculated as a percentage of the maximum possible effect (MPE) according to the following formula: MPE ϭ (latency at 30 min after morphine injection Ϫ latency at preinjection)/(cutoff time Ϫ latency at preinjection) ϫ 100.
Primary culture. Primary cultures of neurons and glia in the spinal cord were prepared as described previously (Urushitani et al., 2006) with minor modifications. The dorsal spinal cords of fetal mice at 14 d of gestation were dissected, minced, and treated with 0.25% trypsin-EDTA for 30 min at 37°C. Cell suspensions plated on 0.1% polyethylenimine-coated (Cui et al., 2009 ), as follows: for NOX3, 5Ј-ctcgttgcctacgggatagc-3Ј and 5Ј-cctt cagcattccttggcct-3Ј; Duox1, 5Ј-ggctgacccatcacctct ac-3Ј and 5Ј-taattgcagggaccaggaag-3Ј; Duox2, 5Ј-ccaaggacgagttcttcacc-3Ј and 5Ј-ccagactcccggaaca taga-3Ј; 18s rRNA, 5Ј-ttcgccatcactgccattaag-3Ј and 5Ј-ctggctgtacttcccatcctt-3Ј; RGS9-2, 5Ј-ggca gctggaagaagaagagaa-3Ј and 5Ј-gagggctctctgtt ctcagtga-3Ј; RGSZ1, 5Ј-cgtcttctggatggcctgtg-3Ј and 5Ј-atgtgttgggatggctccac-3Ј; RGSZ2, 5Ј-cttctg gctggcctgtgaag-3Ј and 5Ј-tcatacatgtgtaggctg gg-3Ј; GAIP, 5Ј-cctcatgcaccgggctcgta-3Ј and 5Ј-ct gtgggccctaaagggtgttgttc-3Ј; and Hprt, 5Ј-aaactttg ctttccctggtta-3Ј and 5Ј-aggctttgtatttggcttttc-3Ј.
Immunohistochemistry. The spinal cord was dissected and quickly embedded in OCT compound. Cryosections were fixed in 4% paraformaldehyde for 1 h and treated with 1% H2O2 to quench endogenous peroxidase. After being blocked with 1% goat serum for 1 h, sections were incubated with an anti-PKC␥ antibody (1:2000) overnight at 4°C, washed with PBS, and incubated with biotinylated anti-rabbit IgG (1:1000) for 1 h. Washed sections were then incubated in avidin-biotin complex solution (1:1000) for 1 h, and developed in diaminobenzidine-H2O2 solution (WinskySommerer et al., 2004) for 30 min.
Dihydroethidium staining and detection of superoxide production. Detection of superoxide production was performed by dihydroethidium (DHE) staining and chemiluminescence using L012 as previously described (Cui et al., 2009; Matsuno et al., 2005) with minor modifications. Frozen spinal cord samples embedded in OCT compound were cut at 10 m and placed on a glass slide. Sections were incubated with 1 M DHE for 20 min at 37°C and then washed three times with PBS. For detection, a 543 nm He-Ne laser combined with a 560 nm long-pass filter was used.
Superoxide production in the dorsal spinal cord was measured with the L012 chemiluminescence assay using a Luminescensor (Atto). Tissue homogenate was prepared in Krebs-HEPES buffer, pH 7.4. Preincubation was performed for 20 min at 37°C and the measurement was started by the addition of 10 M L012. After 15 min, 30 M DPI, an inhibitor of NADPH oxidase, was added and the measurement was continued for another 2 min. Chemiluminescence of L012 was expressed as relative light units (RLU; counts/mg protein/min), calculated by subtracting the count obtained in the presence of DPI.
]GTP␥S)-binding was assayed as described previously (Narita et al., 2001 ) with minor modifications. The dorsal spinal cord was dissected at 2 or 24 h after morphine administration. The crude membrane homogenate was incubated at 30°C for 1 h in binding assay buffer (5 mM MgCl 2 , 1 mM EGTA, and 100 mM NaCl in 50 mM Tris-HCl, pH7.4) with various concentrations of the agonist, 30 M guanosine-5Ј-diphosphate (GDP) and 50 pM [
35 S]GTP␥S (specific activity, 1250 Ci/mmol; PerkinElmer Life Sciences). The reaction was terminated by filtrating through Whatman GF/B glass filters presoaked in 50 mM Tris-HCl, pH7.4, and 5 mM MgCl 2 at 4°C. Filters were washed with ice-cold buffer and the radioactivity was determined by a liquid scintillation counter. 
Measurement of GTPase activity. GTPase activity of spinal cord membrane was determined by measuring [␥-
32 P]GTP (5000 Ci/mmol; Institute of Isotope, Budapest, Hungary) hydrolysis as described previously (Nakagawa et al., 1999) . cpm), 0.1 mM EDTA, 2 mM dithiothreitol, 100 mM NaCl, 5 mM MgCl2, 1 mM ATP, 10 mM creatine phosphate, 2.5 units of creatine phosphokinase, 0.25 mM App(NH)p, 1 mM ouabain, and 10 mM Tris-HCl, pH 7.4]. Unlabeled GTP was added at 0.3 or 1 M. The reaction was continued for 30 min at 30°C and terminated by the addition of 900 l of an ice-cold suspension of 5% (w/v) activated charcoal (Norit A) in 20 mM H3PO4, pH 2.3. After 15 min of centrifugation at 11,000 ϫ g, 500 l of the supernatant was removed, and the amount of 32 Pi released by the hydrolysis of GTP was determined by liquid scintillation counter. Nonspecific GTPase was assessed in the presence of 100 M GTP. Data were corrected for the background and expressed as a percentage of basal GTPase activity.
[ 
H(N)]DAMGO-binding assay.
A selective MOR agonist, [D-Ala(2)-N-MePhe(4)-Gly-ol(5)]enkephalin (DAMGO)-binding was assayed as described previously (Minami et al., 1995) with minor modifications. The crude membrane was resuspended in the buffer for the binding assay. Incubations of membranes with [ 3 H]DAMGO were performed at 25°C for 2 h and the reaction was terminated by filtrating through Whatman GF/B glass filters presoaked with 0.1% polyethylenimine. The filters were washed with ice-cold buffer and the radioactivity was measured by liquid scintillation counting. Nonspecific binding was determined in the presence of 10 M unlabeled DAMGO.
Detection of membrane translocation of PKC isoforms. Apocynin (2 mg/ml in tap water), an inhibitor of NADPH oxidase and an antioxidant (Heumül-ler et al., 2008) , was administered to Nox1 ϩ/Y for 18 d as described previously (Harraz et al., 2008) . TEMPOL (2.9 mol), a membrane-permeable radical scavenger, was injected intrathecally (Schwartz et al., 2008) . Morphine (10 mg/kg, i.p.) was administered immediately after TEMPOL injection. At 2 h after morphine administration, the dorsal spinal cord dissected from mice was homogenized and centrifuged at 1000 ϫ g for 5 min. Supernatants were centrifuged at 10,000 ϫ g for 10 min to remove the mitochondrial fraction, and further centrifuged at 100,000 ϫ g for 30 min at 4°C to obtain the membrane fraction. The resultant pellet dissolved in lysis buffer (25 mM ␤-glycerophosphate, 2 mM EGTA, 1% Triton X-100, 1 mM PMSF, and 2 mM DTT in 25 mM Tris-HCl, pH7.2) was subjected to SDS-PAGE and immunoblot analyses using anti-PKC antibodies.
Immunoprecipitation experiments. The dorsal spinal cord was homogenized in ice-cold 25 mM Tris-HCl, pH7.2, buffer containing 1 mM EGTA and 0.32 M sucrose supplemented with protease and phosphatase inhibitor cocktails. Homogenate was centrifuged at 1000 ϫ g for 5 min and the supernatant was centrifuged at 20,000 ϫ g for 20 min to obtain a crude synaptosomal (P2) fraction. The pellet was washed twice and suspended in immunoprecipitation (IP) buffer (50 mM NaCl, 40 mM octyl-␤-D-glucopyranoside, 0.5 mM NaF, and 2 mM sodium orthovanadate supplemented with the protease inhibitor cocktail in 50 mM TrisHCl buffer, pH7.4). The P2 fraction was then incubated overnight at 4°C with biotinylated IgGs (1 g) raised against the RGS9 or 14-3-3 proteins. These antibodies were first reacted with protein A/G, and purified antibodies were obtained by elution with glycine-HCl, pH2.5, and subsequent neutralization with Tris-HCl, pH9.5. The biotinylation of antibodies was performed using EZ-Link-sulfo-NHS-LCBiotin according to the manufacturer's instructions. Following the addition of NeutrAvidin-agarose (30 l) and incubation for 60 min at 4°C, samples were centrifuged at 1000 ϫ g for 1 min, and supernatant fractions were removed. The agarose pellets were washed five times, centrifuged, and resuspended in IP buffer. The proteins were eluted with Laemmli sample buffer and analyzed by SDS-PAGE, followed by immunoblotting using specific antibodies.
Immunoblotting. Membrane fractions were separated by SDS-PAGE and transferred to PVDF membranes. The membranes were incubated overnight at 4°C with anti-PKC␣, anti-PKC, and anti-PKC␥ antibodies (1:1000); and anti-G␣i2, anti-14-3-3, anti-RGS9-2 antibodies, and phospho-(Ser)PKC substrate antibody (1:2000). After being washed, the membrane was incubated with HRP-conjugated secondary antibodies for 1 h at room temperature, and subsequently with Immobilon Western Chemiluminescent HRP substrate (Millipore). The density of the band was analyzed using ImageJ software.
Statistical analyses. All data are expressed as the mean Ϯ SEM. The statistical significance of differences between groups was assessed with a two-way ANOVA followed by the Bonferroni-Dunn test.
Results

Morphine-induced analgesia was potentiated in Nox1
؊/Y Previously, no difference in locomotor activity and coordinated movement was found between Nox1 ϩ/Y and Nox1 Ϫ/Y (Ibi et al., 2008) . In untreated mice, no significant difference in the threshold for thermal (9.64 Ϯ 0.52 s latency in Nox1 ϩ/Y vs 8.43 Ϯ 0.34 s in Nox1 Ϫ/Y , N ϭ 9 -10) and mechanical (107.32 Ϯ 7.55 g in Nox1 ϩ/Y vs 99.30 Ϯ 6.45 g in Nox1 Ϫ/Y , N ϭ 10) nociceptive stimuli was observed between the two genotypes. In mice treated with intraperitoneal injections of 3 mg/kg morphine, no difference in analgesic effects was observed between the genotypes (data not shown). On the other hand, the effects of 5-10 mg/kg morphine were significantly potentiated in Nox1 Ϫ/Y , which was sustained until 90 min after the injection (F (1,52) ϭ 17.40) (Fig.  1b) . Similar effects were demonstrated in Nox1 , however, no specific signal for NOX1 was detected. Expression of NOX1 mRNA was therefore examined in primary cultures prepared from fetal mouse spinal cord. As shown in Figure 2a , the NOX1 transcript was detected not only in neuronal cells but also in glia. Except for NOX3, all other NOXs, p47phox, p67phox, the organizer subunit NOXO1, and the activator subunit NOXA1 were detected in both cell lineages (data not shown). Similar levels of NOX1 mRNA were expressed in these cells when verified by quantitative realtime PCR (NOX1/18S rRNA ϭ 4.7 ϫ 10 Ϫ3 Ϯ 0.5 ϫ 10 Ϫ3 in neuron vs 5.2 ϫ 10 Ϫ3 Ϯ 0.7 ϫ 10 Ϫ3 in glia, N ϭ 4 -6).
Superoxide production in the dorsal spinal cord was reduced in Nox1
؊/Y MOR is known to occur in laminae I and II of the spinal cord (Polgár et al., 1999) . When superoxide production in the dorsal horn was examined by DHE staining, the fluorescence in Nox1 Ϫ/Y appeared slightly less intense than that in Nox1 ϩ/Y (Fig. 2b) . In accord with these findings, superoxide production assessed by DPIsensitive L012 chemiluminescence (RLU) was significantly attenuated in Nox1 (F (1,168) ϭ 0.53). Opioid receptor signaling involves the intrinsic GTPase activity of the G␣ subunit dissociated from the receptor following interaction with GTP. Hydrolysis of GTP dictates the duration of G␣-GTPand G␤␥-mediated signaling. We therefore examined the GTPase activity in the presence of 0.3 M GTP or 1 M GTP, at a concentration at which opioid agonists activate the GTPase activity of the Gi/o and Gz/q/11 protein, respectively (Garzó n et al., 1997). As shown in Figure 3b , addition of morphine dosedependently increased GTP hydrolysis in the membrane fraction obtained from Nox1 ϩ/Y , but not from Nox1 Ϫ/Y (F values of 0.3 M GTP and 1 M GTP are F (1,67) ϭ 8.35, F (1,56) ϭ 9.61). On the other hand, mRNA levels of RGS proteins that regulate MOR agonist signaling were similar in both genotypes (Fig. 3c) . These findings suggest that NOX1/NADPH oxidase may modulate opioid receptor signaling downstream of G-protein activation, without affecting the level of RGS expression.
Morphine-induced activation of GTPase was suppressed in Nox1
Morphine-induced analgesic tolerance was suppressed in Nox1
؊/Y Next, we investigated the role of NOX1 in morphine-induced tolerance. At 24 h after the initial administration of morphine (10 mg/kg), mice were treated with the same amount of morphine, and analgesic effects against thermal stimuli were determined. As shown in Figure 4a 11.49) (Fig. 4b) . Intriguingly, these findings were in line with a previous study demonstrating that NADPH oxidase inhibitors blocked the development of chronic morphine-induced tolerance (Doyle et al., 2010) . Since the difference in analgesic effects between the genotypes was apparent as early as 24 h after the first administration of morphine, we subsequently focused on the regulatory mechanisms of NOX1/NADPH oxidase in the induction of acute analgesic tolerance to morphine. (Fig. 5b) . These findings suggest the involvement of MOR in NOX1/NADPH oxidase-mediated development of acute analgesic tolerance to morphine. (Table 1) .
[ 35 S]-GTP␥S-binding was preserved in
Morphine-induced translocation of PKC was attenuated in Nox1
Since previous studies showed the involvement of PKC isoforms in tolerance to morphine (Bilsky et al., 1996; Bailey et al., 2006) , we next examined the activation of PKC following morphine administration. Among PKC isoforms, PKC␣ and in the dorsal root ganglion, as well as PKC␣ and ␥ in the spinal cord, were known to take part in morphine-induced tolerance (Smith et al., 2007) . At 2 h after the morphine injection, the translocation of PKC␣, PKC, and PKC␥ to the membrane fraction of the dorsal spinal cord was markedly increased in Nox1 ϩ/Y , whereas it was significantly suppressed in Nox1 Ϫ/Y (F values of PKC␣, PKC, and PKC␥ are F (1,20) ϭ 26.31, F (1,20) ϭ 10.76, F (1,20) 6a). Consistent with these findings, the translocation of PKC isoforms was significantly attenuated in Nox1 ϩ/Y administered with an antioxidant apocynin for 18 d (F values of PKC␣, PKC, and PKC␥ are F (1,15) ϭ 11.03, F (1,15) ϭ 7.05, F (1,15) ϭ 4.57), or with TEMPOL before morphine administration (F values of PKC␣, PKC, and PKC␥ are F (1,15) ϭ 6.58, F (1,15) ϭ 5.71, F (1,15) ϭ 7.78) (Fig. 6b,c) . No apparent abnormal behavior was observed in mice during chronic administration of apocynin. These findings suggest that ROS derived from NOX1/NADPH oxidase modulate the translocation of PKC isoforms in the dorsal spinal cord induced by morphine.
Morphine-induced phosphorylation of RGS9-2, formation of G␣i2/RGS9-2/14-3-3, and degradation of G␣i2 were attenuated in Nox1
The results obtained in [
35 S]GTP␥S and [ 3 H]DAMGO-binding assays suggested the uncoupling of the MOR and G␣ protein, rather than the receptor's internalization, to be involved in the desensitization induced by morphine. One of the mechanisms documented for uncoupling is the formation of a G␣, RGS9-2, and 14-3-3 proteins complex (Garzó n et al., 2005) . The formation of this complex is accompanied by serine phosphorylation of RGS9-2. RGS9-2 has the putative 14-3-3-binding motif, K(K/ S)DpSY(P/A), and the PKC consensus sequence, (K/R)XXS. We therefore examined the phosphorylation of the target serine residue of PKC in RGS9-2 using a phospho-(Ser)PKC substrate antibody. As shown in Figure 7a , phosphorylation of RGS9-2 was significantly increased at 1 h after morphine administration in Nox1 ϩ/Y , whereas it was significantly suppressed in Nox1 Ϫ/Y (F (1,32) ϭ 4.24). In accordance with these findings, increased coprecipitation of RGS9-2 and G␣i2 with 14-3-3 proteins depicted in Nox1 ϩ/Y was significantly blunted in Nox1 Ϫ/Y treated with morphine (F values of RGS9-2 and G␣i2 are F (1,28) ϭ 9.24, F (1,24) ϭ 9.95) (Fig. 7b) . Moreover, a significant decrease in G␣i2 at 24 h after morphine administration in the crude membrane homogenate was abolished in Nox1 Ϫ/Y , suggesting that the dissociation of G␣i2 from the membrane was attenuated by Nox1 deficiency (F (1,28) ϭ 6.77) (Fig. 7c) .
Discussion
We presently demonstrated a novel role for NOX1/NADPH oxidase in morphine-induced analgesia and analgesic tolerance. The principal findings obtained were as follows: (1) . (6) The formation of a complex by G␣i2 and RGS9-2 with 14-3-3 proteins and subsequent degradation of G␣i2 were significantly attenuated in . Based on these findings, it is reasonable to conclude that NOX1-derived ROS negatively regulate the analgesic effects of morphine.
Regardless of the route of administration, morphine-induced analgesia was significantly augmented in Nox1 Ϫ/Y . Metabolized primarily in the liver, morphine is converted into morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) (Kilpatrick and Smith, 2005) . M3G does not bind to the opioid receptor and has no analgesic effect, while M6G binds to MOR and elicits more potent effects than morphine (van Dorp et al., 2006) . In our study, the effects of the intrathecal administration of morphine were potentiated in Nox1 Ϫ/Y similar to the findings obtained in intraperitoneally treated mice. Accordingly, our results suggest that the increased analgesic effects in Nox1 Ϫ/Y are not attributable to the enhanced metabolic conversion of morphine into M6G.
While no difference in morphine-induced activation of G-protein was observed between the genotypes, GTP hydrolysis was activated by the addition of morphine in the spinal cord membrane of Nox1 ϩ/Y , but not of Nox1 Ϫ/Y . Since previous studies demonstrated the upregulation of RGS2 expression caused by oxidative stress (Zmijewski et al., 2001) , we examined whether the expression of RGS mRNAs was affected by the Nox1 deficiency. G␣ proteins are inactivated by RGSZ1, RGSZ2, and GAIP (Hollinger and Hepler, 2002) , while RGS9-2 associated with G␣ has limited GAP activity (Lan et al., 2000) . No difference in mRNA levels of these RGS proteins was observed between the genotypes. The mechanisms underlying the NOX1-mediated activation of GTPase by morphine are therefore still unclear. ROS derived from NOX1 may directly accelerate the hydrolysis of GTP by G␣, as documented for small GTPases (Heo, 2011) , or augment the GAP activity of the RGS protein through posttranslational modifications (Willars, 2006) . In fact, NOX1-derived ROS induced an intramolecular disulfide formation in low molecular weight tyrosine phosphatase to increase phosphorylation of p190RhoGAP, a GTPase-activating protein for Rho (Shinohara et al., 2007 3 H]DAMGO to the spinal cord membrane was unaffected. These findings indicate that morphine elicits desensitization without an apparent change in the number of MOR. This is in agreement with previous studies, which found that morphineinduced desensitization took place without ␤-arrestin-mediated MOR internalization (Johnson et al., 2006; Groer et al., 2007) . Most relevantly, it was demonstrated that the initial exposure to morphine causes G␣ depletion due to the interaction of G␣ with RGS, while further exposure to morphine elicits phosphorylation and internalization of MOR (Rodríguez-Muñoz et al., 2007) . Since the maximal binding of [ 3 H]DAMGO was determined after a single administration of morphine, our results were in accord with these earlier findings.
The increased phosphorylation of RGS9-2 in morphinetreated Nox1 ϩ/Y was significantly suppressed in Nox1 Ϫ/Y . RGS proteins are not simply GTPase-activating proteins, but are also involved in the regulation of G-protein-effector interactions (Abramow-Newerly et al., 2006) . The decrease in the interaction of MOR with G␣ and resultant sequestering of MOR-activated G␣ could be attributed to the interaction of RGS9-2 with 14-3-3 proteins, which is facilitated by PKC-dependent Ser-phosphorylation of RGS9-2 (Garzó n et al., 2005) . Consistent with this, the formation of a complex by RGS9-2/G␣i2 with 14-3-3 proteins and dissociation of G␣i2 from the membrane were markedly increased in Nox1 ϩ/Y following morphine administration, and suppressed by the Nox1 deficiency. Accordingly, RGS9-2 appears to be a target of PKC affected by ROS derived from NOX1 (Fig. 8) . Of interest in this regard, the phenotype of Nox1 Ϫ/Y treated with morphine resembled that reported in RGS9-downregulated or RGS9-deficient mice that showed increased analgesia and delayed tolerance (Garzó n et al., 2001; Zachariou et al., 2003) .
A critical issue to be addressed is the molecular mechanism underlying the NOX1-mediated activation of PKC demonstrated in this study. We previously reported that ROS derived from NOX1/NADPH oxidase in dorsal root ganglia (DRG) neurons modulate transient receptor potential vanilloid 1 (TRPV1) in a PKC-dependent manner.
In DRG neurons, ROS derived from NOX1 enhance the translocation of PKC via modulation of the redox state of cysteine residues located at the C1A site (Ibi et al., 2008) . The colocalization of PKC␥ immunoreactivity and DHE fluorescence in the dorsal spinal cord suggests that NOX1-mediated activation of PKC also takes place in a way similar to that in DRG neurons. The signaling pathways involved in the recruitment of PKC␥ to RGS proteins and MOR have been intensively studied , 2011 . The physical interaction with activated PKC may easily phosphorylate RGS proteins and increase their binding to 14-3-3 proteins (Garzó n et al., 2005) .
In conclusion, we demonstrated a novel role for NOX1 in morphine-induced analgesia and induction of acute tolerance. NOX1/NADPH oxidase attenuates the analgesic effects of morphine, possibly by accelerating the hydrolysis of GTP by G␣. Furthermore, ROS derived from NOX1 augment analgesic tolerance to morphine by activating PKC and then ensuing the formation of a complex by G␣ and RGS9-2 with 14-3-3 proteins. The present study provides the first evidence that NOX1/NADPH oxidase is the source of ROS implicated in the modulation of morphine-related analgesia and tolerance. The NOX1 isoform may thus be a novel target for the development of effective adjuvant therapy to maintain the beneficial effects of morphine.
